Immunotech Laboratories Announces LOI With International Bio-Tech
Partner For USA Clinical Trials Funding Of Patented HIV Medicines
PASADENA, Calif., Jan. 29, 2013 /PRNewswire/ -- Immunotech
Laboratories, Inc. (PINKSHEETS: IMMB) today announced the
company has been in negotiations with an International Bio-Tech
Partner in the HIV cure technology sector for joint advanced
Research & Development and the partner has agreed to provide
the necessary funding for the USA
Clinical Trials phases to ultimately achieve FDA approval for the
medicines.
A senior spokesperson for Immunotech further added, the terms
while yet to be fully determined include some exclusive rights for
the International partner for use and distribution of the vaccines
in several countries where the equivalent of FDA approval is not
required and can be distributed and administered labeled as an
"Experimental Drug". This process will help accelerate the clinical
trials results.
Pursuant to significantly positive results with its patient
population targeting full blown AIDS patients, the company has
completed numerous clinical contracts with Mexican hospitals to
initiate a full blown effort of clinical trial protocol preparation
for its HIV/AIDS Vaccine drug candidate. The successful outcome of
these efforts will eventually provide the necessary regulatory
means for its product's registration approval in the Republic of
Mexico and eventually open a venue
to most of the central and South American markets.
Further information can be obtained from
www.immunotechlab.com
Safe Harbor Statement: This news release contains
forward-looking statements that involve risks and uncertainties
associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other
risks described by Immunotech Laboratories, Inc. from time to time
in its periodic reports filed with the SEC. IPF is not approved by
the US Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Immunotech Laboratories
believes that the forward-looking statements and underlying
assumptions contained therein are reasonable, any of the
assumptions could be inaccurate, including, but not limited to, the
ability of Immunotech Laboratories to establish the efficacy of IPF
in the treatment of any disease or health condition, the
development of studies and strategies leading to commercialization
of IPF in the United States, the
obtaining of funding required to carry out the development plan,
the completion of studies and tests on time or at all, and the
successful outcome of such studies or tests. Therefore, there can
be no assurance that the forward-looking statements included in
this release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, Immunotech Laboratories or any other person that the
objectives and plans of Immunotech Laboratories will be achieved
should not regard the forward-looking statements as a
representation.
Contact: Harry Zhabilov
President and Chief Science Officer
Telephone: 818-409-9091
Investor Relations
IR@immunotechlab.com
Contact
CSNNewswire.com
310-467-6521
info@csnnewswire.com
SOURCE Immunotech Laboratories, Inc.